University of Geneva (UNIGE) is Switzerland's second-largest university, founded in 1559 by John Calvin. Located in the heart of Europe on Lake Geneva, the university has established itself as a leading institution in neuroscience research, particularly in neurodegenerative diseases[@university2024]. The university's strategic location near the World Health Organization, CERN, and numerous international organizations creates unique opportunities for interdisciplinary collaboration.
University of Geneva (UNIGE) is Switzerland's second-largest university, founded in 1559 by John Calvin. Located in the heart of Europe on Lake Geneva, the university has established itself as a leading institution in neuroscience research, particularly in neurodegenerative diseases[@university2024]. The university's strategic location near the World Health Organization, CERN, and numerous international organizations creates unique opportunities for interdisciplinary collaboration.
The Memory Center at Geneva University Hospitals (HUG) serves as the primary clinical and research hub for neurodegenerative disease research. This center integrates memory clinic services, neuroimaging facilities, and basic science laboratories to provide comprehensive care and advance understanding of Alzheimer's disease and related disorders[@geneva2023].
Research Programs
Neuroimaging Research Initiative
The University of Geneva has established one of Europe's most advanced neuroimaging programs:
PET/MRI Integration: State-of-the-art hybrid PET/MRI scanners enable simultaneous acquisition of molecular and structural neuroimaging data, allowing researchers to examine the relationship between amyloid deposition, tau pathology, and brain atrophy in unprecedented detail[@frisoni2023].
Structural Connectivity: Advanced diffusion tensor imaging (DTI) and tractography techniques characterize white matter damage in early Alzheimer's disease and predict disease progression.
Functional Imaging: resting-state and task-based fMRI studies investigate default mode network disruptions and their relationship to cognitive decline.
Biomarker Development Program
Geneva researchers lead European consortia developing fluid and imaging biomarkers:
Blood-based Biomarkers: Collaboration with pharmaceutical partners to validate plasma tau, neurofilament light chain (NfL), and amyloid ratios for screening and disease monitoring[@milani2024].
CSF Biomarkers: Extensive biobank of cerebrospinal fluid samples enables longitudinal studies of biomarker dynamics from pre-symptomatic through advanced disease stages.
Precision Medicine: Integration of biomarker data with genetic profiling to develop personalized risk stratification approaches.
Clinical Trials Program
The Memory Center actively participates in international clinical trials:
Anti-amyloid Therapies: Participation in Phase 2/3 trials of monoclonal antibodies targeting various forms of amyloid-beta[@van2023].
Tau-targeted Approaches: Involvement in trials of tau aggregation inhibitors and anti-tau antibodies.
Lifestyle Interventions: The FINGER trial network conducts lifestyle modification studies examining diet, exercise, cognitive training, and vascular risk management.
Key Research Groups
Neuroimaging Group
Led by [Giovanni B. Frisoni](/researchers/giovanni-b-frisoni), this group focuses on:
Development and validation of novel MRI biomarkers for Alzheimer's disease
Application of machine learning to neuroimaging data for early detection
Multi-center neuroimaging harmonization and standardization
Basic Neuroscience Group
[Patrick G. Hof](/researchers/patrick-hof) leads investigations into:
Cellular and molecular mechanisms of neurodegeneration
Neuroinflammation in aging and Alzheimer's disease
Synaptic dysfunction and loss in early disease stages
Clinical Trials
| Trial Name | Phase | Focus | Status | |------------|-------|-------|--------| | EPAD | Longitudinal | Early Alzheimer's prevention | Active | | AMYPAD | Diagnostic | Amyloid PET imaging | Completed | | ALzheimer's Disease Neuroimaging Initiative 3 | Observational | Biomarker validation | Active |
Key Researchers
| Researcher | H-index | Focus Areas | |------------|---------|-------------| | [Giovanni B. Frisoni](/researchers/giovanni-b-frisoni) | 180 | Alzheimer's Disease, Neuroimaging | | [Jakob P. Wiss](/researchers/jakob-wiss) | 40 | Alzheimer's Disease, Biomarkers | | Patrick G. Hof | 65 | Neuropathology, Cellular mechanisms | | Nicolas R. Blat | 55 | Neuroimaging, MRI methods |
Contributions to the Field
Hippocampal atrophy classification: Development of standardized MRI-based hippocampal atrophy ratings used worldwide.
EMIF-AD biomarker platform: Leadership in European biomarker validation consortia.
Diagnostic criteria contributions: Active participation in revisions to IWG and NIA-AA diagnostic criteria.
Neuroimaging harmonization: Pioneering work on Centiloid standardization for amyloid PET.
External Links
Official Website: [https://www.unige.ch/](https://www.unige.ch/)